N
Nina Kimmeskamp-Kirschbaum
Researcher at Bayer HealthCare Pharmaceuticals
Publications - 8
Citations - 905
Nina Kimmeskamp-Kirschbaum is an academic researcher from Bayer HealthCare Pharmaceuticals. The author has contributed to research in topics: Finerenone & Cmax. The author has an hindex of 6, co-authored 8 publications receiving 637 citations. Previous affiliations of Nina Kimmeskamp-Kirschbaum include Bayer Corporation.
Papers
More filters
Journal ArticleDOI
Effect of finerenone on albuminuria in patients with diabetic nephropathy : a randomized clinical trial
George L. Bakris,Rajiv Agarwal,Juliana C.N. Chan,Mark E. Cooper,Ron T. Gansevoort,Hermann Haller,Giuseppe Remuzzi,Peter Rossing,Roland E. Schmieder,Christina Nowack,Peter Kolkhof,Amer Joseph,Alexander Pieper,Nina Kimmeskamp-Kirschbaum,Luis M. Ruilope +14 more
TL;DR: Finerenone demonstrated a dose-dependent reduction in UACR, and among patients with diabetic nephropathy, the addition of finerenone compared with placebo resulted in improvement in the urinary albumin-creatinine ratio.
Journal ArticleDOI
A randomized controlled study of finerenone vs. eplerenone in patients with worsening chronic heart failure and diabetes mellitus and/or chronic kidney disease
Gerasimos Filippatos,Stefan D. Anker,Michael Böhm,Mihai Gheorghiade,Lars Køber,Henry Krum,Aldo P. Maggioni,Piotr Ponikowski,Adriaan A. Voors,Faiez Zannad,So Young Kim,Christina Nowack,Giovanni Palombo,Peter Kolkhof,Nina Kimmeskamp-Kirschbaum,Alexander Pieper,Bertram Pitt +16 more
TL;DR: Finerenone was well tolerated and induced a 30% or greater decrease in NT-proBNP levels in a similar proportion of patients to eplerenone in patients with worsening heart failure and reduced ejection fraction and chronic kidney disease and/or diabetes mellitus.
Journal ArticleDOI
Rationale and design of MinerAlocorticoid Receptor antagonist Tolerability Study-Heart Failure (ARTS-HF): a randomized study of finerenone vs. eplerenone in patients who have worsening chronic heart failure with diabetes and/or chronic kidney disease
Bertram Pitt,Stefan D. Anker,Michael Böhm,Mihai Gheorghiade,Lars Køber,Henry Krum,Aldo P. Maggioni,Piotr Ponikowski,Adriaan A. Voors,Faiez Zannad,Christina Nowack,So Young Kim,Alexander Pieper,Nina Kimmeskamp-Kirschbaum,Gerasimos Filippatos +14 more
TL;DR: To investigate the safety and potential efficacy of the novel non‐steroidal mineralocorticoid receptor antagonist finerenone in patients with worsening chronic heart failure and reduced left ventricular ejection fraction and at high risk of hyperkalaemia and worsening renal dysfunction.
Journal ArticleDOI
Pharmacokinetics, safety and tolerability of the novel, selective mineralocorticoid receptor antagonist finerenone - results from first-in-man and relative bioavailability studies.
TL;DR: In conclusion, finerenone has favourable pharmacokinetics and tolerability in healthy men, and is suitable for dosing independent of food intake, as well as enhanced bioavailability versus PEG solution.
Journal ArticleDOI
Pharmacokinetics of the Novel Nonsteroidal Mineralocorticoid Receptor Antagonist Finerenone (BAY 94-8862) in Individuals With Renal Impairment.
TL;DR: In participants with moderate or severe renal impairment, exposure to finerenone was increased compared with those with normal renal function, and changes in exposure may occur because of the effects of renal impairment on nonrenal routes of elimination.